Drug intelligence / Profile preview

GC1140B

Development stage: Preclinical
Lead developer: 绿十字
Modality: Vaccines & Immunotherapeutics

Overview

GC1140B is a vaccine candidate developed by Green Cross (GC Biopharma) currently in preclinical development for the prevention or treatment of Epstein-Barr virus (EBV) infection. The vaccine is intended to elicit an active immune response against EBV, a member of the herpesvirus family associated with infectious mononucleosis and several types of cancer, including certain lymphomas and nasopharyngeal carcinoma.

Targets

gp350 (Epstein-Barr virus glycoprotein 350)

Beyond the preview

Go deeper on GC1140B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC1140B.

Explore the full profile